Playing Catch-Up with Optogenetic Effects
Optogenetically Triggered Processes Needn’t Become Visualization and Mapping Blurs
Why Cardiology Is the Next Frontier for Precision Medicine
Cardiovascular Disease Applications Are Set to Focus on Highly Individualized Variables for Therapy
New Paradigms to Maximize Partnering Value in Biotech
Some Key Considerations for Life Sciences Companies Evaluating Collaboration Agreements
Tricks of the Trade for Cell Culture Optimization
Cell Culture Knowhow Encompasses Scale-Down Modeling, Inline Sampling, and Other Practicalities
For full access to this article login to GEN Select now.
Road to Antibiotic Approval Made Clearer
Regulatory Hurdles Are Higher, but a New Well-Defined Path Means We Know How High to Jump
- Antibiotic development has become a challenging therapeutic area. Shifting and evolving regulatory guidelines have made design of clinical trials difficult and the prospect for marketing approval fairly low. In addition, the short-term treatment regimens have made the sector relatively unattractive from a return on investment perspective, particularly for antibiotics ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.